Shao-An Xue
Human MHC Class I-restricted high avidity CD4 + T cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo
Xue, Shao-An; Gao, Liquan; Ahmadi, Maryam; Ghorashian, Sara; Barros, Rafael D; Pospori, Constandina; Holler, Angelika; Wright, Graham; Thomas, Sharyn; Topp, Max; Morris, Emma C; Stauss, Hans J.
Authors
Liquan Gao
Maryam Ahmadi
Sara Ghorashian
Rafael D Barros
Constandina Pospori
Angelika Holler
Dr Graham Wright G.Wright2@napier.ac.uk
Associate Professor
Sharyn Thomas
Max Topp
Emma C Morris
Hans J. Stauss
Abstract
In this study, we generated human MHC Class I-restricted CD4+ T cells specific for Epstein-Barr virus (EBV) and cytomegalovirus (CMV), two herpesviridae associated with lymphoma, nasopharyngeal carcinoma and medulloblastoma, respectively. Retroviral transfer of virus-specific, HLA-A2-restricted TCR-coding genes generated CD4+ T cells that recognized HLA-A2/peptide multimers and produced cytokines when stimulated with MHC Class II-deficient cells presenting the relevant viral peptides in the context of HLA-A2. Peptide titration revealed that CD4+ T cells had a 10-fold lower avidity than CD8+ T cells expressing the same TCR. The impaired avidity of CD4+ T cells was corrected by simultaneously transferring TCR- and CD8-coding genes. The CD8 co-receptor did not alter the cytokine signature of CD4+ T cells, which remained distinct from that of CD8+ T cells. Using the xenogeneic NOD/SCID mouse model, we demonstrated that human CD4+ T cells expressing a specific TCR and CD8 can confer efficient protection against the growth of tumors expressing the EBV or CMV antigens recognized by the TCR. In summary, we describe a robust approach for generating therapeutic CD4+ T cells capable of providing MHC Class I-restricted immunity against MHC Class II-negative tumors in vivo.
Citation
Xue, S., Gao, L., Ahmadi, M., Ghorashian, S., Barros, R. D., Pospori, C., …Stauss, H. J. (2013). Human MHC Class I-restricted high avidity CD4 + T cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo. OncoImmunology, 2(1), Article e22590. https://doi.org/10.4161/onci.22590
Journal Article Type | Article |
---|---|
Acceptance Date | Jan 1, 2013 |
Online Publication Date | Oct 27, 2014 |
Publication Date | 2013-01 |
Deposit Date | Aug 1, 2016 |
Publicly Available Date | Jun 28, 2023 |
Journal | OncoImmunology |
Print ISSN | 2162-4011 |
Electronic ISSN | 2162-402X |
Publisher | Taylor & Francis |
Peer Reviewed | Peer Reviewed |
Volume | 2 |
Issue | 1 |
Article Number | e22590 |
DOI | https://doi.org/10.4161/onci.22590 |
Keywords | CMV, EBV, TCR gene transfer, antitumor therapy, high avidity CD4 T cells, virus associated cancer |
Public URL | http://researchrepository.napier.ac.uk/Output/320454 |
Additional Information | This study was supported by grants from Leukaemia and Lymphoma Research, Experimental Cancer Medicine Centre, ATTACK EU Consortium, MRC Clinical Training Fellowship, MRC/UCL Virology Centre and MRC-DPFS. We would like to thank Dr. P.H. Tan for his kind help with some of the intracellular cytokine staining experiments. |
Files
Human MHC Class I-restricted high avidity CD4 + T cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo
(1.8 Mb)
PDF
Publisher Licence URL
http://creativecommons.org/licenses/by-nc/3.0/
You might also like
Therapeutic potential of Tregs to treat rheumatoid arthritis
(2011)
Journal Article
CD3 limits the efficacy of TCR gene therapy in vivo
(2011)
Journal Article
Natural IgM Is Required for Suppression of Inflammatory Arthritis by Apoptotic Cells
(2011)
Journal Article
Downloadable Citations
About Edinburgh Napier Research Repository
Administrator e-mail: repository@napier.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search